FDA final guidance defines when companion app output counts as drug labeling and when device-connected or standalone apps belong in prescribing information.
|Articles|December 2, 2003
- Pharmaceutical Technology-12-02-2003
- Volume 27
- Issue 12
Drug Pricing Concerns Shape Policy Decisions in 2003
Author(s)Jill Wechsler
FDA initiatives aim to spur the development of more-affordable treatments and ensure safe product use.
Advertisement
Articles in this issue
almost 23 years ago
December 2003almost 23 years ago
All Signs Indicate a Strong 2004 for Contract Servicesalmost 23 years ago
Behavior of Uptake of Moisture by Drugs and Excipientsalmost 23 years ago
Targeted Cationic Liposomes, Technologies, and Developmentsalmost 23 years ago
Sixth Annual International Employment Survey: Staying the Coursealmost 23 years ago
In the Spotlight--January 2004almost 23 years ago
December 2003Advertisement
Related to this article
Boyang Wang of Immortal Dragons explains how FDA's Expedited IND Pilot and QRIs could compress sequential first-in-human steps as China's Decree 818 raises the pace.
Ravi Kiran Kaja, PhD, explains how USP’s industry-wide initiative aims to build confidence in trace-level extractables and leachables results.
Science, circularity, regulation, and technology are reshaping how the industry develops packaging for medicines.
Panelists on PharmTech AI Pulse Check debate SURPASS, a new digital-twin trial program, regulatory acceptance, and the data-cleanup burden it will create.
The deadline to comment on FDA's generative AI paper is Oct 19, 2026. We explain why professionals in pharma manufacturing should weigh in.
The FDA expanded Anktiva to BCG-unresponsive papillary-only NMIBC using existing CIS trial data, a precedent with implications for development timelines and supply planning.
AI accountability, faster FDA pathways, rare disease CMC review, and next-gen GLP-1 formulation lead this week’s PharmTech roundup.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Germany’s Medical Biotechnology Sector is Flourishing
2
OpenAI Bets on Accelerating Drug Development Timelines With Orchestra Bio
3
PharmTech AI Pulse Check: Why Pharma Should Weigh In on FDA's Generative AI Paper
4
Sustainability in Healthcare Packaging: The Journey From Yesterday to Tomorrow
5